References

Neuroleptic malignant syndrome: Still a risk, but which patients may be in danger?
Adityanjee, Aderibigbe, YA, Mathews, T: Epidemiology of Neuroleptic malignant syndrome. Clinical Neuropharmacology, 1999; 2:151-158.

Adityanjee, Mathews T, Aderibigbe YA: Proposed research diagnostic criteria for neuroleptic malignant syndrome. International Journal of Neuropsycholpharmacology, 1999; 2:129-144.

Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin No Amer, 1993; 185-202.

Caroff SN, Mann SC, Keck PE, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol, 2000; 20: 257-259.

Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals, 2000; 30 (5):314-321.

Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol, 1998; 18: 349-351.

Current Psychiatry, December 2003
Stanley N. Caroff, M.D

Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatric Annals, 2000; 30 (5):325-331.

Davis JM, Janicak PG, Sakkas P, et al: Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convulsive Therapy, 1991; 7:111-120.

Francis, A., Divadeenam, K., Petrides, G. Advances in treatment of catatonia with lorazepam and ECT, Convulsive Therapy, 1996; 12:259-261.

Francis, A., Koch, M., Chandragiri S., Rizvi, S., Petrides, G. Is Lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectrums, 2000 (In Press).

Fricchione GE, Mann SC, Caroff SN. Catatonia, lethal catatonia, and neuroleptic malignant syndrome. Psychiatric Annals, 2000; 30:347-355.

Gelenberg AJ, Bellinghausen B, Wojcik JD, et al: Patients with neuroleptic malignant syndrome histories: What happens when they are rehospitalized? J Clin Psychiatry, 1989; 50: 178-180.

Gupta S: New Approaches to the treatment of dopamine blocking agent induced movement disorders: Drug-Induced Movement Disorders, Editor Sethi KD, Marcel Dekker, Inc. New York (2004)

Gupta S, Racaniello AA: Neuroleptic malignant syndrome associated with Amoxapine and Lithium in an older adult. Annals of Clinical Psychiatry, 2000; 12:107-109.

Gupta S, Nihalani N: Neuroleptic Malignant Syndrome: A primary care perspective. Primary Care Companion J Clin Psychiatry 2004; 6:191-194

Gurrera RJ, Chang SS: Thermoregulatory dysfunction in neuroleptic malignant syndrome. Biol Psychiatry, 1996; 39:207-212.

Gurrera RJ: Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry, 1999; 156: 169-180.

Gurrera RJ: Diaphoresis and dehydration during neuroleptic malignant syndrome: preliminary findings. Psychiatry Res, 1996; 64:137-145.

Keck, PE, Arnold, LM: Seretonin syndrome. Psychiatric Annals, 2000; 30 (5):333-343.

Keck PE, Caroff SN, McElvroy SL. Neuroleptic malignant syndrome and malignant hyperthermiaÐend of a controversy? J Neuropsychiatry Clin Neurosci, 1995; 7 135-144.

Keck PE, Pope HG, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry, 1989; 46: 914-918.

Koch, M., Chandragiri, S., Rizvi, S., Petrides, G, and Francis, A. Catatonic signs in neuroleptic malignant syndrome, Comprehensive Psychiatry, 2000; 41: 73-75.

Lazarus A, Mann SC, Caroff SN: The Neuroleptic Malignant Syndrome and Related Conditions. Washington DC, American Psychiatric Press Inc., 1989.

Mann SC, Caroff SN, Fricchione GE, Campbell EC: Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatric Annals, 2000; 30 (5):363-374 .

Mann SC, Caroff SN, Bleier HR, et al. Lethal catatonia. Am J Psychiatry, 1986; 1374-1381.

Mann SN, Caroff SN, Bleier HR, et al. Electroconvulsive therapy in the treatment of lethal catatonia: case report and review. Convulsive Therapy, 1990; 6: 239-247.


Rosebush PI, Stewart TD, Gelenberg AJ: Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry, 1989; 50: 295-298.

Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146: 717-775.

Velamoor VR, Swamy GN, Parmar RS, et al: Management of suspected neuroleptic malignant syndrome. Can J Psychiatry, 1995; 40: 545-550.